Literature DB >> 18398761

Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders.

Angel L Montejo1, Fernando Rico-Villademoros.   

Abstract

Sexual dysfunction is a disturbing and often underrecognized problem associated with schizophrenia and its treatment. The Psychotropic-Related Sexual Dysfunction (PRSexDQ-SALSEX) is a brief and relatively nonintrusive questionnaire that has shown adequate psychometric properties in patients with depression. This study examined the psychometric properties of the PRSexDQ-SALSEX in a sample of patients with schizophrenia or other psychotic disorders who were experiencing anti-psychotic-induced sexual dysfunction and were switched to olanzapine. The PRSexDQ-SALSEX was very feasible and its internal reliability was satisfactory. In addition, this questionnaire showed a good convergent validity and sensitivity to tracking changes in sexual functioning.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398761     DOI: 10.1080/00926230701866125

Source DB:  PubMed          Journal:  J Sex Marital Ther        ISSN: 0092-623X


  10 in total

1.  Exercise improves sexual function in women taking antidepressants: results from a randomized crossover trial.

Authors:  Tierney Ahrold Lorenz; Cindy May Meston
Journal:  Depress Anxiety       Date:  2014-03       Impact factor: 6.505

2.  The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.

Authors:  Angel L Montejo; Laura Montejo; David S Baldwin
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

3.  Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: rates vary with assessment questionnaire.

Authors:  Naresh Nebhinani; Sandeep Grover; Ajit Avasthi
Journal:  Prim Care Companion CNS Disord       Date:  2012-04-26

4.  Sexual dysfunctions in schizophrenia: Professionals and patients perspectives.

Authors:  Hema Tharoor; Anandhalakshmi Kaliappan; Subhashini Gopal
Journal:  Indian J Psychiatry       Date:  2015 Jan-Mar       Impact factor: 1.759

Review 5.  Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach.

Authors:  Angel L Montejo; Nieves Prieto; Rubén de Alarcón; Nerea Casado-Espada; Javier de la Iglesia; Laura Montejo
Journal:  J Clin Med       Date:  2019-10-07       Impact factor: 4.241

6.  Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients.

Authors:  Nuria García-Marchena; Nieves Pizarro; Francisco J Pavón; Miriam Martínez-Huélamo; María Flores-López; Nerea Requena-Ocaña; Pedro Araos; Daniel Silva-Peña; Juan Suárez; Luis J Santín; Rafael de la Torre; Fernando Rodríguez de Fonseca; Antonia Serrano
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

Review 7.  Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach.

Authors:  Angel L Montejo; Rubén de Alarcón; Nieves Prieto; José Mª Acosta; Bárbara Buch; Laura Montejo
Journal:  J Clin Med       Date:  2021-01-15       Impact factor: 4.241

8.  Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders.

Authors:  Juan J Ruíz Ruíz; José M Martinez Delgado; Nuria García-Marchena
Journal:  Harm Reduct J       Date:  2021-04-13

9.  Depression, Sexual Dysfunction, and Medical Comorbidities in Young Adults Having Nicotine Dependence.

Authors:  Ranjan Bhattacharyya; Debasish Sanyal; Sumita Bhattacharyya; Kaustav Chakraborty; Rajarshi Neogi; Bejoy Bikram Banerjee
Journal:  Indian J Community Med       Date:  2020-09-01

10.  Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone.

Authors:  Hong Liu-Seifert; Bruce J Kinon; Christopher J Tennant; Jennifer Sniadecki; Jan Volavka
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.